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Summary
Background Multiple sclerosis is the most common inflammatory neurological disease in young adults. The Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic method of quantifying various 
effects of a given condition by demographic variables and geography. In this systematic analysis, we quantified the 
global burden of multiple sclerosis and its relationship with country development level.
Methods We assessed the epidemiology of multiple sclerosis from 1990 to 2016. Epidemiological outcomes for multiple 
sclerosis were modelled with DisMod-MR version 2.1, a Bayesian meta-regression framework widely used in GBD 
epidemiological modelling. Assessment of multiple sclerosis as the cause of death was based on 13 110 site-years of 
vital registration data analysed in the GBD’s cause of death ensemble modelling module, which is designed to choose 
the optimum combination of mathematical models and predictive covariates based on out-of-sample predictive validity 
testing. Data on prevalence and deaths are summarised in the indicator, disability-adjusted life-years (DALYs), which 
was calculated as the sum of years of life lost (YLLs) and years of life lived with a disability. We used the Socio-
demographic Index, a composite indicator of income per person, years of education, and fertility, to assess relations 
with development level.
Findings In 2016, there were 2 221 188 prevalent cases of multiple sclerosis (95% uncertainty interval [UI] 
2 033 866–2 436 858) globally, which corresponded to a 10·4% (9·1 to 11·8) increase in the age-standardised prevalence 
since 1990. The highest age-standardised multiple sclerosis prevalence estimates per 100 000 population were in 
high-income North America (164·6, 95% UI, 153·2 to 177·1), western Europe (127·0, 115·4 to 139·6), and Australasia 
(91·1, 81·5 to 101·7), and the lowest were in eastern sub-Saharan Africa (3·3, 2·9–3·8), central sub-Saharan African 
(2·8, 2·4 to 3·1), and Oceania (2·0, 1·71 to 2·29). There were 18 932 deaths due to multiple sclerosis (95% UI 
16 577 to 21 033) and 1 151 478 DALYs (968 605 to 1 345 776) due to multiple sclerosis in 2016. Globally, age-standardised 
death rates decreased significantly (change –11·5%, 95% UI –35·4 to –4·7), whereas the change in age-standardised 
DALYs was not significant (–4·2%, –16·4 to 0·8). YLLs due to premature death were greatest in the sixth decade of life 
(22·05, 95% UI 19·08 to 25·34). Changes in age-standardised DALYs assessed with the Socio-demographic Index 
between 1990 and 2016 were variable.
Interpretation Multiple sclerosis is not common but is a potentially severe cause of neurological disability throughout 
adult life. Prevalence has increased substantially in many regions since 1990. These findings will be useful for 
resource allocation and planning in health services. Many regions worldwide have few or no epidemiological data on 
multiple sclerosis, and more studies are needed to make more accurate estimates.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Multiple sclerosis is the most common inflammatory 
neurological disease in young adults. The mean age of 
diagnosis is approximately 30 years, with most patients 
presenting with periodic neurological relapses.1 One to 
two decades after onset, many patients with multiple 
sclerosis enter a progressive phase of the disease. Several 
environmental factors and genetic alleles might alter the 
risk of developing multiple sclerosis, but the under­
lying cause of the disease remains elusive.2,3 Common 
neurological manifestations of multiple sclerosis include 
optic neuritis, diplopia, sensory loss, limb weakness, gait 
ataxia, loss of bladder control, and cognitive dysfunction. 
15 medications have been approved by the US Food and 
Drug Administration to reduce the number of relapses 
and attenuate progression of neurological disability.1 
These drugs are partly effective, but whether they alter the 
long­term course of multiple sclerosis remains unclear.4
The epidemiology of multiple sclerosis has been the 
subject of many studies. Over the past five decades, 
prevalence has been rising across North America and 
Europe, high incidence has been seen among women and 
among African Americans, and persistent geo graphical 
risk gradients have been documented.5–9 Contemporary 
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reviews have provided updates on the prevalence, inci­
dence, and burden of multiple sclerosis in the Americas,5 
Europe,6 and worldwide.7 The MS International Federation 
has compiled a useful inter national atlas of the epi­
demiology of multiple sclerosis with detailed country­level 
data, but this group did not use systematic modelling for 
disease morbidity, mortality, and risk factors.10 The lack 
of standardisation in the methods of epidemiological 
studies limits comparisons of findings and assessments 
of multiple sclerosis with those of other conditions. 
Additionally, few evaluations have been done at the 
country level, epidemiological data in different ethnic 
groups are incomplete, and many regions of the world 
remain to be studied.
The Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) provides a systematic method of 
quantifying health loss in great detail for a given condition 
by demographic variables and geographical location.11 
By using information from the literature, population 
statistics, and rigorous algorithms, a consistent picture is 
produced across the major regions of the world. Com­
parisons of multiple sclerosis with other common neuro­
logical conditions were reported by the GBD 2015 
Neurological Disorders Collaborator Group.12 In 2015, 
multiple sclerosis ranked tenth for prevalence among 
neurological conditions measured, with 2 012 000 cases 
estimated globally.12 Prevalence of multiple sclerosis and 
disability­adjusted life­years (DALYs) were significantly 
higher in women than in men, and there were significant 
gradients in prevalence and incidence across different 
regions of the world.
In this systematic analysis, we present new estimates 
of the global burden of multiple sclerosis from 1990 to 
2016 (measured by prevalence, mortality, DALYs, years of 
life lived with disability [YLDs], and years of life lost 
[YLLs]), and assess the relation with development level, 
as measured by the Socio­demographic Index (SDI). The 
GBD approach provides a perspective on the burden of 
multiple sclerosis relevant to researchers, clinicians, and 
health policy makers.
Methods
The general methods of GBD 2016 are summarised in the 
appendix, and we present here the methods specific to the 
estimation of multiple sclerosis. This study complies with 
the Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER) recommendations. Fur­
ther details on GBD 2016 data, analysis, and results are 
available online.
Mortality
The International Classification of Diseases code for 
multiple sclerosis is 340 in the ninth edition and G35 in 
the tenth edition. Modelling of causes of death related to 
multiple sclerosis was based on 13 110 site­years of data (ie, 
a combination of GBD locations and calendar years of vital 
Research in context
Evidence before this study
We searched PubMed for studies published between 2011 and 
2015 that were representative, population-based surveys, 
including retrospective case-report and hospital-report analyses 
and nationally representative health studies. The search string 
used was “multiple sclerosis AND epidemiology AND 
(2011/01/01: 2015/12/31)”. Additional searches for features 
such as prevalence, disability-adjusted life-years, years of life 
lost, and mortality are reviewed in the appendix. Global 
estimates of prevalence, incidence, and deaths from multiple 
sclerosis have been made in past iterations of the Global Burden 
of Diseases, Injuries, and Risk Factors Study (GBD). Other 
epidemiological studies have focused on variations in 
prevalence and incidence of multiple sclerosis between 
individual countries and noted marked differences along 
latitude gradients. Similar data have been recorded on a map 
produced by the MS International Federation. The GBD study 
uses an integrated modelling approach to predict morbidity and 
mortality in countries and regions of the world from where 
there are insufficient data. Previously, estimates for multiple 
sclerosis have been summarised in GBD reports about other 
diseases, but no report has focused exclusively on this disease.
Added value of this study
This Article presents the methods and results for a focused GBD 
2016 analysis of multiple sclerosis, making use of detailed 
country-level morbidity and mortality data. We have explored 
variation in the burden of multiple sclerosis by country 
development level, as measured by the Socio-demographic 
Index, which is a composite indicator of income per person, 
years of education, and fertility.
Implications of all the available evidence
Multiple sclerosis is quite rare but is a potentially severe cause 
of neurological disability. Onset is typically in young adulthood, 
after which symptoms persist throughout adult life. Prevalence 
has increased in many world regions, due in part to improved 
survival. These findings are relevant to researchers, clinicians, 
and health policy makers. The health service needs of the 
increasing number of patients with multiple sclerosis must be 
considered. Several disease-modifying therapies have been 
developed that reduce the number of relapses and slow 
neurological disability, at least during the early phases of the 
disease. Although expensive, these medications are important 
components of comprehensive multiple sclerosis care, along 
with rehabilitation and access to multidisciplinary care. More 
national, epidemiological studies in multiple sclerosis are 
needed for GBD to generate more robust worldwide estimates 
in the future.
See Online for appendix
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registration data) and analysed in the GBD cause of 
death ensemble modelling tool (CODEm). The model 
used predictive covariates, including population­weighted 
average latitude by country, mean cholesterol, the GDB 
Healthcare Access and Quality Index, the cumulative 
number of cigarettes consumed over the previous 5 and 
10 years, education, lag­distributed income, and SDI (a 
composite indicator of income per person, years of 
education, and fertility; appendix). The choice of covariates 
was based on any reported putative relationship with 
multiple sclerosis mortality, but does not imply any causal 
relationships. CODEm is designed to assess which com­
bination of covariates best helps to fit a model to the 
available input data by use of out­of­sample predictive 
validity testing.
Modelling of prevalence and incidence
The reference case definition of multiple sclerosis for GBD 
is based on the 2005 McDonald criteria.13 We also 
incorporated data with alternative definitions, including 
the Poser criteria,14 Schumacher’s criteria,15 Allison and 
Millar criteria,16 Bauer criteria,17 and McAlpine criteria 
(appendix).18 Other sources reporting on medical claims 
data using International Classification of Diseases codes 
or general practice codes from the UK were also used. 
From a systematic review, 167 unique sources informing 
the epidemiological model for multiple sclerosis were 
identified. We added US medical claims data from 3 years 
(2000, 2010, and 2012). We found 129 unique sources on 
prevalence and 65 unique sources on incidence, covering 
13 of the 21 GBD world regions (appendix). No data were 
available for southeast Asia, Oceania, eastern Europe, the 
Caribbean, Andean Latin America, central sub­Saharan 
Africa, southern sub­Saharan Africa, and western sub­
Saharan Africa. We used the GATHER checklist to define 
reporting practices for studies, like the GBD study, that 
calculate health estimates for multiple populations using 
multiple data sources (appendix).19
Epidemiological outcomes for multiple sclerosis were 
modelled with DisMod­MR 2.1, a Bayesian meta­regression 
framework widely used in GBD epidemio logical modell­
ing. This framework combines data on prevalence, in­
cidence, remission, and mortality into one model. We set 
incidence to zero among children younger than 4 years 
and assumed no remission (ie, no full cure). Study co­
variates were included to adjust the US claims data for 
2000 and 2010, which we found to be system atically lower 
than claims data for 2012. SDI was included as a covariate 
on prevalence, average latitude as a covariate on prevalence 
and incidence, and the GBD Healthcare Access and 
Quality Index as a covariate on excess mortality (ie, excess 
deaths in people with multiple sclerosis compared with 
mortality in people without multiple sclerosis; appendix).
Severity distributions and years lived with disability
We identified four separate health states of multiple 
sclerosis based on disability level: mild, moderate, severe, 
and asymptomatic. The latter category represents people 
who have a diagnosis of multiple sclerosis but no overt 
symptoms. In the GBD Disability Weight Surveys,20 short 
lay descriptions were written to capture the main 
symptoms, reported according to Kurtzke’s Expanded 
Disability Status Scale21 and assuming that scores of 
0 indicate asymptomatic disease, scores greater than 0 up 
to 3·5 indicate mild multiple sclerosis, those greater than 
3·5 and up to 6·5 indicate moderate multiple sclerosis, 
and scores greater than 6·5 indicate severe disease 
(appendix).21 A systematic review of studies with severity 
data according to the Expanded Disability Status Scale 
identified 27 unique sources, covering ten of 21 GBD world 
regions. However, only 14 of these studies sep arated people 
with scores of 0, whereas the other studies included scores 
of 0 in the mild category. To make use of all available data 
on severity, a two­step meta­analytical approach was 
developed. First, we did a meta­analysis of studies with 
data on the proportion of people with asymptomatic 
multiple sclerosis to de termine the pro portions of those 
with asymptomatic or mild multiple sclerosis included in 
the overall mild category. We did the second meta­analysis 
on all avail able data on the proportion of the total mild 
category (asymptomatic and mild combined) and the 
proportions of moderate and severe multiple sclerosis. 
Finally, the proportions of asymptomatic and mild from 
the first meta­analysis were scaled to the total mild category 
that was generated in the second meta­analysis to estimate 
the final proportions for the four health state categories. 
The prevalence estimates for each severity state were 
multiplied by the corresponding disability weights to 
derive un corrected YLDs. These initial YLD estimates 
were sub sequently corrected for comorbidity with the 
comorbidity correction simulation developed for GBD.22
Risk estimation
Relative risk data were pooled with a meta­analysis of 
cohort, case­control, and intervention studies. Risks and 
outcomes were paired, and for each we evaluated the 
evidence and judged whether the evidence fell into the 
categories of convincing or probable, as defined by the 
World Cancer Research Fund.23 From the prevalence 
and relative risk results, population­attributable fractions 
were estimated relative to the theoretical minimum 
risk exposure level. When we aggregated estimates for 
clusters of risks, such as metabolic or behavioural risks, 
we used a multiplicative function rather than simple 
addition, taking into account how much of each risk is 
mediated through another risk. The choice of covariates 
was based on any reported putative relationship with 
multiple sclerosis morbidity, but does not imply any 
causal relationships. 
Smoking was the only environmental risk of 84 risks 
quantified in GBD 2016 that we judged to have sufficient 
evidence for a causal relationship with multiple scler­
osis as an outcome.24 Population­based surveys were the 
main source of data for the smoking exposure model. 
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
Global 18 932 
(16 577 to 21 033)
–11·5% 
(–35·4 to –4·7)
2 221 188 
(2 033 866 to 2 436 858)
10·4% 
(9·1 to 11·8)
1 151 478 













(23 152 to 38 812)
12·9% 
(–5·8 to 31·0)









(132 266 to 189 475)
14·1% 
(–6·9 to 41·3)









(142 543 to 193 030)
14·4% 
(–4·0 to 34·5)









(180 033 to 270 242)
–10·6% 
(–20·1 to 3·1)
High SDI 10 021 
(7385 to 10 873)
2·9% 
(–34·2 to 12·1)
1 227 486 













































































(7938 to 11 957)
21·9% 
(–1·5 to 37·7)





































































































































































(24 904 to 37 142)
12·9% 
(–3·8 to 25·4)
(Table continues on next page)
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)


















































































































































































(49 758 to 69 626)
12·4% 
(–11·2 to 19·6)
















































Central Europe, eastern Europe, and central Asia

















































































(38 194 to 71 187)
–4·2% 
(–27·9 to 36·6)
(Table continues on next page)
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)










(15 211 to 27 804)
6·2% 
(–20·0 to 37·5)
































































































































































































































































































Latin America and Caribbean









(16 674 to 24 408)
37·3% 
(–12·7 to 53·3)
(Table continues on next page)
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
(Continued from previous page)


































































































Southeast Asia, east Asia, and Oceania





















(59 718 to 80 673)
–4·9% 
(–27·4 to 15·2)
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)































































































































































North Africa and Middle East
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)


















































































(16 029 to 26 706)
3·0% 
(–15·0 to 20·6)
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Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
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Population­attributable fractions were estimated based 
on these exposure data, along with data on relative risk 
and a theoretical minimum level of exposure, which for 
smoking was no lifetime exposure to tobacco smoke. 
Criteria for inclusion of risks into GBD include the 
availability of sufficient evidence for a causal relationship 
between a risk and one or more disease or injury outcome; 
evidence to support generalisability of an effect size 
beyond the populations included in epidemio logical 
studies; availability of sufficient data and methods to 
enable estimation of exposure levels by country; and the 
likely importance of a risk factor to disease burden or 
policy considerations. Additional details on risk factor 
calculations have been described elsewhere.25
Compilation of results
YLLs were calculated by multiplying the number of deaths 
in each age group by the remaining life expectancy for that 
age group, as determined by the GBD standard life table.26 
DALYs were calculated as the sum of YLLs and YLDs. 
Uncertainty was propagated through all calcu lations by 
sampling 1000 draws at each step of the calculations, 
carrying through uncertainty from input data, corrections 
of measurement error, and estimates of residual non­
sampling error. Uncertainty intervals (UIs) were defined 
as the 25th and 975th values of the ordered draws. The 
significance of changes between 1990 and 2016 was based 
on the 95% UI of the change estimate, not including zero.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation or the writing 
of the report. The corresponding authors had full access 
to all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
In 2016, an estimated 2 221 188 people worldwide had 
multiple sclerosis (95% UI 2 033 866–2 436 858), corre­
sponding to a prevalence of 30·1 cases (95% UI 27·5–33·0) 
per 100 000 population. Age­standardised pre valence 
estim ates increased by 22·47 cases (95% UI 20·5–24·61) 
Deaths (95% uncertainty interval) Prevalence (95% uncertainty interval) DALYs (95% uncertainty interval)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)
2016 counts Percentage change in 
age-standardised rates 
between 1990 and 
2016 (%)











































































































































































DALY=disability-adjusted life-years. SDI=Socio-demographic Index. 
Table: Deaths, prevalence, and DALYs for multiple sclerosis in 2016, and percentage change of age-standardised rates by location
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per 100 000 population or 10·4% (9·1–11·8) between 1990 
and 2016 (table). Age­standardised preva lence was greater 
than 120 cases per 100 000 population in North America 
and some northern European countries, moderate 
(60–120 per 100 000) in some countries in Europe and 
Australasia, and lowest (<60 per 100 000 population) in 
North Africa and the Middle East, Latin America, Asia, 
Oceania, the Caribbean, and sub­Saharan Africa (figure 1). 
Of note, in low prevalence regions, many countries had 
no data and modelling was used to generate estimates 
(appendix). Detailed estimates on morbidity and mortality 
by year (1990–2016) and geographical region can be found 
on the GBD 2016 Global Health Data Exchange. Age­
standardised prevalence of multiple sclerosis changed 
most in the east Asia region (44·8% increase) and Canada 
(81·9% increase) between 1990 and 2016. The highest age­
standardised multiple sclerosis prevalence estimates per 
100 000 population were in high­income North America 
(164·6, 95% UI, 153·2–177·1), western Europe (127·0, 
115·4–139·6), and Australasia (91·1, 81·5–101·7), and the 
lowest were in eastern sub­Saharan Africa (3·3, 2·9–3·8), 
central sub­Saharan Africa (2·8, 2·4–3·1), and Oceania 
(2·0, 1·71–2·29)
We found a gradient for prevalence from low to high 
between low and high SDI quintiles. The greatest change 
in multiple sclerosis prevalence between 1990 and 2016 
was seen in the middle SDI quintile, with an increase in 
prevalence of 41·3% (changes in other quintiles were 
increases of 30·6% in the high quintile, 18·7% in the 
high­middle quintile, 33·1% in the low­middle quintile, 
and 23·0% in the low quintile). We found a significant 
association between prevalence and latitude. The co­
efficient of average latitude in our DisMod­MR model 
was 1·03 (95% UI 1·03–1·04) per degree of latitude 
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Prevalence of multiple sclerosis (per 100 000 population)
Figure 1: Age-standardised multiple sclerosis prevalence per 100 000 population in 2016 for both sexes, by location
ATG=Antigua and Barbuda. Isl=Islands. LCA=Saint Lucia. VCT=Saint Vincent and the Grenadines. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micornesia.


























Figure 2: Age-standardised prevalence of multiple sclerosis in 2016, by age 
and sex
Shading shows 95% uncertainty intervals.
For more on the GBD 2016 
Global Health Data Exchange 
see http://ghdx.healthdata.org
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preval ence between countries at the equator and the 
highest population­weighted average latitude of 74·7º.
The global prevalence of multiple sclerosis differs sub­
stantially by sex (figure 2). Among preteen children, the 
prevalence of multiple sclerosis is similar in boys and girls. 
During adolescence, the curves start to diverge, with the 
prevalence increasing more among girls than boys. This 
pattern continues until around the end of the sixth decade 
of life, when the sex ratio is 2:1 in favour of women. In older 
people, prevalence generally continues to climb for women, 
but a slow attenuation in prevalence is seen for men.
Globally, there were 18 932 deaths due to multiple 
sclerosis (95% UI 16 577–21 033) in 2016 (table). Most 
deaths occurred in high SDI countries (10 021 95% UI 
7358–10 873), and mortality in the USA was highest 
among all countries (3862 deaths, 2743–4226). Between 
1990 and 2016, the age­standardised mortality rate for 
multiple sclerosis globally decreased by 11·5%, but 
changes by region and country were mostly not signifi­
cant because of wide uncertainty intervals (table).
The effect on YLLs due to premature death and dis­
ability was greatest in the sixth decade of life (22·05, 
95% UI 19·08–25·34) rising steeply beforehand and 
dropping substantially afterwards (figure 3). For YLDs, 
the curve rises to a peak at age 55 years, stabilises, then 
climbs slightly higher during the eighth decade of life 
and more steeply thereafter (figure 3).
The global DALYs for multiple sclerosis in 2016 totalled 
1 151 478 (95% UI 968 605 to 1 345 776) representing a non­
significant decrease of 4·2% (95% UI –16·4 to 0·8) from 
1990 (table). Countries in the SDI highest SDI quintile 
accounted for half of the DALYs in 2016 (577 314 DALYs 
[50%] of 1 151 478 worldwide). Overall, multiple sclerosis 
made up 0·04% (95% UK 0·04 to 0·05) of the overall 
DALYs from all neurological dis orders, as shown on the 
GBD 2016 website.27
The relationship between age­standardised DALYs and 
SDI over time for each of the 21 GBD regions, represented 
as annual time series from 1990 and 2016, are shown in 
figure 4. Age­standardised DALYs rose substantially over 
time for high­income North America, western Europe, and 
Australasia. By contrast, in central Europe and eastern 
Europe age­adjusted DALYs declined while SDI increased. 
However, among all changes only the increase in high­
income North America was significant (table). Among 
high­income regions, high­income Asia Pacific had DALYs 
that were much closer to those of low­income and middle­
income regions.
Of the global DALYs due to multiple sclerosis, 99 076 
(95% UI 62 164–140 650) or 8·6% (95% UI 5·6–11·7) were 
estimated to be due to smoking.
Discussion
With the rigorous standardised GBD approach for mor­
bidity assessments, we estimated that there were around 
2·2 million cases of multiple sclerosis worldwide in 2016. 
In that year, prevalence was 10·4% higher than in 1990. 
Multiple sclerosis also contributed 0·04% (95% UI 
0·04−0·05) of total DALYs and 0·05% (0·04−0·07) of all 
YLLs in 2016. Although neurological disability progression 
is variable, DALYs peaked in the sixth decade of life. 
Because onset is most frequently in early adulthood and 
because survival has been improved, people with multiple 
sclerosis are affected throughout adult life, leading to the 
high number of YLDs. The disability weights for multiple 
sclerosis are generally high (appendix) and YLDs begin to 
increase steeply early in the second decade of life.
We found a strong latitude gradient for the prevalence 
of multiple sclerosis, with an increase in prevalence of 
1·03 times per degree of latitude. A north to south decrease 
in prevalence by latitude gradient has been recognised in 




























Figure 3: YLDs and YLLs due to multiple sclerosis in 2016, by age
Shading shows 95% uncertainty intervals. YLDs=years lived with disability. 
YLLs=years of life lost.
Figure 4: Age-standardised DALYs for multiple sclerosis by SDI, 1990–2016, and expected value-based SDI
The black line represents the average expected relationship between SDI and DALYs for multiple sclerosis based on 
values from all countries over the 1990–2016 estimation period. DALYs= disability-adjusted life-years. 
SDI=Socio-demographic Index.
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North America and western Europe,28,29 and a reverse south 
to north increase in gradient has been reported in 
Australia.28 Temporal trends in prevalence show that these 
gradients were weakening in the 20th century,9 but the 
distribution of multiple sclerosis can still be generally 
described as having three zones of frequency or risk 
(figure 1), as originally proposed by Kurtzke.30 In 2016, 
northern European countries and North America made up 
the high­risk prevalence zone, with estimates of 100 or 
more cases of multiple sclerosis per 100 000 population. 
These regions are bounded by areas of medium frequency 
(prevalence 30–100 cases per 100 000). Low­frequency areas 
are centred around the equator, and the prevalence in Asia 
is less than 30 cases per 100 000 population. Geographical 
location before onset of multiple sclerosis remains a risk 
factor for acquisition.28 Clear gradients from low to high 
prevalence between low and high SDI quintiles are 
reported on the GBD 2016 website. The burden of multiple 
sclerosis was greatest in the regions with the highest 
socioeconomic status. These gradients point to environ­
mental risk factors that modulate risk based on location.
Prevalence of multiple sclerosis differed substantially 
over the adult life of women and men. Rising mul­
tiple sclerosis morbidity among women in the later 
20th century has been reported in studies of multiple 
sclerosis prevalence and incidence.7,30 An analysis of data 
from the Danish Multiple Sclerosis Registry showed that 
incidence in women doubled between 1950 and 2009, 
whereas increases among men have been more modest.31 
By contrast, excess mortality among patients with mul­
tiple sclerosis in Denmark has declined since 1950.32 
Environmental changes that might be contributing to the 
rapid change in incidence among women include the 
rise in obesity, increased cigarette smoking, and changes 
in the frequency of breastfeeding infants.31,33
Our results are consistent with some previous reports 
of multiple sclerosis morbidity from around the world. 
Canadian studies have indicated the highest mul­
tiple sclerosis prevalence estimates so far. In the prov­
ince of British Columbia, prevalence was 179·9 cases 
per 100 000 population in 2008.34 This value is close to our 
estimate for all of Canada, which fell into the band 
of 150–180 cases per 100 000 population. However, an 
estimate of 266·9 cases per 100 000 popu lation in Nova 
Scotia from 201035 is substantially higher. The prevalence 
of multiple sclerosis reported from European regions has 
been variable, with values being higher in northern than in 
southern regions. For example, national prevalence of 
154·5 cases per 100 000 was reported in Denmark in 2005,36 
and an estimate of 230·6 cases per 100 000 population in 
Northern Ireland was reported in 2008.37 A meta­analysis 
suggests pre valence below 100 cases per 100 000 population 
in France and southern and eastern Europe.6 Studies of 
multiple sclerosis prevalence in South America have 
largely been done in small regions, but a study from 
Panama produced a national crude prevalence of 5·2 per 
100 000,38 which is notably lower than the estimates for 
North America. Studies in Africa have been sparse and 
those from Asia have had variable quality.39 Nevertheless, 
our world map of multiple sclerosis prevalence is similar 
to the 2013 MS International Federation world atlas for 
multiple sclerosis morbidity by country and region.10
Incidence of multiple sclerosis has been relatively stable 
or slightly increased over the past four to five decades in 
white populations, but has been higher in selected racial 
groups.7–9 Therefore, the rising prevalence estimates for 
multiple sclerosis across high­income regions and coun­
tries might mostly reflect improved survival.40 In addition, 
the diagnostic criteria for multiple sclerosis have evolved 
and earlier diagnosis is possible with the use of neuro­
imaging, and these factors are likely to be con tributing to 
the increased prevalence observed.41
Genetic susceptibility to multiple sclerosis is an im­
portant factor that influences risk for onset.3 Multiple 
sclerosis is considered to be a complex genetic disease, 
with over 200 alleles having been discovered to contribute 
small risk effects.3 Yet the rapid changes by sex, race, and 
ethnicity in incidence and prevalence over the past 
few generations give support to environmental factors 
as drivers of susceptibility to multiple sclerosis.9 Prime 
candidates include infection, such as with the Epstein­Barr 
virus or other organisms, as the initiator of multiple 
sclerosis,42 with the suggestion that infections start in the 
gut and spread to the CNS.42,43 Environmental exposures, 
such as smoking,44 lack of sunlight,45 diet,46 changes in the 
gut microbiome,47 and obesity,48 have also received support 
as risk factors for onset of multiple sclerosis.
The GBD 2016 neurological data related to multiple 
sclerosis provide a pathway for priority setting and service 
planning in health care in relation to other disorders. 
The rising cost of multiple sclerosis disease­modifying 
medications is a major global concern.49 Ensuring access 
to disease­modifying medi cations as well as rehabilitation 
and multidisciplinary care will help to slow disability 
progression and support independence in daily activities 
for patients with multiple sclerosis. Ageing of the large 
multiple sclerosis popu lation in North America and 
Europe will be important for health­care providers and 
policy makers to assess patients’ future health­service 
needs.50 Ways to provide adaptive work environments and 
cost­effective nursing care options to patients will be 
important for policy planners in regions where prevalence 
is increasing.
The GBD methods have limitations for the epidemio­
logical assessment of multiple sclerosis. First, data are 
absent or extremely sparse for many regions of the world, 
including Latin America, sub­Saharan Africa, and Asia. 
As such, the models we used to predict prevalence, DALYs, 
and YLLs might lead to unusual changes in segments of 
the data. For example, the rapid increases in prevalence in 
women older than 80 years and the YLD curve we 
estimated should be viewed with caution because they are 
not typical of individual population­based studies. We 
cannot exclude that the relatively low burden of multiple 
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sclerosis in less­developed countries was related to the 
underdiagnosis of the condition due to limited access to 
specialised medical care, imaging resources, and labo­
ratory investigations. Additionally, even in high­income 
regions where multiple sclerosis is well studied, there are 
few national prevalence and incidence studies, and case­
ascertainment infrastructures are limited. For example, in 
Greenland our estimate for multiple sclerosis prevalence 
was based on one study in a small community of fewer 
than 2000 inhabitants, in which no cases of multiple 
sclerosis were found between 1950 and 1974.51 The un­
certainty around this mean incidence value of 0 per 
100 000 incidence is so wide that it is compatible with a 
high prevalence, as predicted by our latitude covariate. We 
acknowledge that with additional epidemiological data 
this high estimate for Greenland might be altered, but 
until such information becomes available we maintain 
that the results from our model are valid.
A second major limitation was the lack of robust 
predictive covariates for multiple sclerosis to aid in 
population­based risk assessments,24 which was due partly 
to the limited pool of longitudinal neurological disability 
data that is representative of the multiple sclerosis 
population. We found a significant relationships between 
multiple sclerosis, prevalence, latitude, level of develop­
ment. However, by including both covariates we might 
have underestimated the effect of latitude because of 
collinearity between SDI and distance from the equator. 
Inclusion of SDI as a covariate might also have spuriously 
led to increasing estimates of prevalence over time. 
Latitude remains a proxy and, therefore, an uncertain 
predictor for multiple sclerosis as long as there is no 
established biological basis for the relationship. With 
sparse data and uncertain predictive covariates, we cannot 
exclude that some of the variation measured in prevalence 
is due to measurement error.
One way forward for the assessment of the global 
burden of multiple sclerosis is to use a validated algorithm 
approach to estimate prevalence and incidence in popul­
ation­based health care administrative datasets.52 This 
approach has been successfully applied to North American 
multiple sclerosis populations.40,52 The availability of medi­
cal claims data from the USA makes us more confident of 
the estimates for that country. GBD is actively seeking 
access to medical claims data in other countries to improve 
the accuracy of estimates for diseases such as multiple 
sclerosis, for which every patient can be expected to be in 
contact with the health­care system if there are no major 
barriers to accessing care. Through our network of 
collaborators, we expect future iterations of GBD to be 
able to add such sources from other countries.
In summary, multiple sclerosis is an important cause of 
neurological disability throughout adult life. This report 
gives an integrated, contemporary understanding of the 
global multiple sclerosis disease burden. Prevalence has 
increased partly due to improved survival. The GBD 
approach to estimating multiple sclerosis morbidity and 
mortality is novel and can be repeated with relative 
efficiency. Our findings will be useful for resource 
allocation and health services planning for the growing 
numbers of patients with multiple sclerosis in ageing 
societies. More national multiple sclerosis epidemiological 
studies, especially from low­income and middle­income 
countries, are needed for the GBD Multiple Sclerosis 
collaborators to generate robust worldwide estimates in 
the future.
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